Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. (2016)

First Author: James ND
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(15)01037-5

PubMed Identifier: 26719232

Publication URI: http://europepmc.org/abstract/MED/26719232

Type: Journal Article/Review

Volume: 387

Parent Publication: Lancet (London, England)

Issue: 10024

ISSN: 0140-6736